ticker stringlengths 2 5 | disease stringlengths 3 196 | stage stringclasses 15 values | date stringlengths 6 8 | catalyst stringlengths 20 963 | label int64 4 6 |
|---|---|---|---|---|---|
IPHA | Non-small cell lung cancer (NSCLC) | Phase 2 | 9/17/21 | Phase 2 trial met primary endpoint of confirmed ORR of 30%, and for durvalumab plus monalizumab 36%. The 10-month PFS rate was 64.8% for the durvalumab plus oleclumab combination and 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone, September 17, 2021. | 6 |
AMGN | Acute lymphoblastic leukemia (ALL) - pediatric | Phase 3 | 9/24/19 | Phase 3 enrolment terminated due to treatment benefit over chemo. Primary endpoint of event-free survival met. | 6 |
ABBV | Alzheimer’s disease | Phase 2 | 9/7/23 | Phase 2 enrollment to be completed, noted September 7, 2023. | 5 |
GILD | Urothelial Cancer | Approved | 4/13/21 | FDA approval announced April 13, 2021. | 6 |
CGEM | Non-Small Cell Lung Cancer | Phase 1/2 | 12/16/21 | Updated Phase 1/2a reported that 14 patients achieved a confirmed PR for a 39% confirmed response rate and one additional patient had a PR that was pending confirmation at the time of the data cut-off. The median duration of response was >15 months and the median progression free survival was 12 months in the initial cohort of Phase 1 patients, noted December 16, 2021. | 6 |
ABBV | Age-related macular degeneration (AMD) | CRL | 6/26/20 | CRL issued June 26, 2020. | 5 |
NVS | Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis | Approved | 3/21/23 | Approved March 21, 2023. | 6 |
REGN | Homozygous familial hypercholesterolemia (HoFH) in children | Approved | 3/22/23 | Approved March 22, 2023. | 6 |
INCY | Non-Small-Cell Lung Cancer (NSCLC) | Phase 2 | 5/19/21 | Phase 2 data in ASCO abstract noted ORR of 65.6% for the treatment-naive expansion Cohort 7. | 6 |
LLY | Cancer pain | Phase 3 | 7/28/21 | Phase 3 trial met primary endpoint - July 2021. | 6 |
MRNA | Ovarian cancer | Phase 2 | 8/5/21 | Development has been discontinued - noted August 5, 2021. | 4 |
ANNX | Geographic atrophy | Phase 2 | 7/30/23 | Phase 2 results presented at ASRS demonstrated dose and time-dependent protection of visual function in GA across multiple measures, noted July 30, 2023. | 6 |
SWTX | Desmoid tumors | Phase 3 | 9/10/22 | Phase 3 data presented at ESMO resulted in rapid, sustained and statistically significant Improvements in primary and all Key secondary efficacy endpoints, noted September 10, 2022. | 6 |
BPTH | Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) | Phase 2 | 8/1/23 | Phase 2 interim analysis reported that in cohort 1, twelve of the fourteen evaluable patients (86%) achieved complete remission (CR/CRi) and two (14%) achieved partial remission (PR), and in cohort 2 eight of the fourteen evaluable patients (57%) achieved complete remission (CR/CRi), two (14%) achieved partial remission (PR) and three (22%) achieved stable disease, noted August 1, 2023. | 6 |
PCRX | Postoperative Pain Management | Phase 3 | 9/21/21 | Phase 3 study found the PK profile was comparable across age groups and generally consistent with the profile in adult patients. No safety concerns were identified at a dose of 4 mg/kg, noted September 21, 2021. | 6 |
TNGX | Solid Tumors | Phase 1a | 9/6/23 | IND cleared by FDA, noted September 6, 2023. Phase 1/2 clinical trial to commence 1H 2024. | 5 |
ETON | Lennox-Gastaut syndrome, epilepsy | CRL | 5/27/22 | CRL announced May 27, 2022. | 5 |
GILD | Adult patients with r/r ALL - cancer | Approved | 10/1/21 | Approved October 1, 2021. | 6 |
CALC | Wet age-related macular degeneration | Phase 2b | 11/15/21 | Additional Phase 2b data reported that the anatomical control was similar to aflibercept over 18 months with BCVA maintained in extension study, noted November 15, 2021. | 5 |
BPMC | Advanced Systemic mastocytosis (SM) | Approved | 6/16/21 | FDA approval announced June 16, 2021. | 6 |
VYNE | Vitiligo | Phase 1b | 10/30/23 | Phase 1b clinical proof-of-concept achieved with statistically significant dose dependent reduction in F-VASI score from baseline for the VYN201 1.0% and 2.0% cohorts compared to the 0.5% cohort, noted October 30, 2023. | 6 |
KTRA | Glioblastoma (GBM) | Phase 2/3 | 10/31/23 | Phase 2/3 data reported that it did not perform better than the current standards of care in glioblastoma, noted October 31, 2023. | 5 |
AKRO | Nonalcoholic steatohepatitis (NASH) | Phase 2b | 10/10/23 | Phase 2b top line data showed that a trend was observed for the primary endpoint of fibrosis improvement at 36 weeks, with 22% and 24% of the 28mg and 50mg EFX-treated groups, respectively, compared with 14% for placebo, noted October 10, 2023. | 6 |
ALEC | Alzheimer’s disease | Phase 1 | 11/10/21 | Phase 1 data demonstrated target engagement of CD33 in both blood and central nervous system (CNS) compartments at well tolerated doses in healthy volunteers, noted November 10, 2021. | 6 |
AERI | Open Angle Glaucoma | Phase 3 | 9/24/20 | Phase 3 top-line data released September 24, 2020. Non-inferiority to Ganfort achieved. | 6 |
GILD | Nonalcoholic steatohepatitis (NASH) | Phase 2 | 12/16/19 | Phase 2 trial did not meet primary endpoint - December 16, 2019. | 4 |
CGTX | Alzheimer's Disease | Phase 1/2 | 3/28/23 | Additional biomarker data revealed 28 biomarkers that were significantly altered as a result of treatment with CT1812, 11 of which are priority biomarkers of Alzheimer's biology, noted March 28, 2023. | 6 |
ALLO | Non-Hodgkin lymphoma (NHL) | Phase 1 | 6/15/23 | Phase 1 data update presented at ICML and ASCO 23 reported that 7 of 12 (58%) patients achieved a CR and five (42%) maintained a CR through Month 6. Of the five patients who were in CR at 6 months, four (80%) remained in CR, noted June 15, 2023. | 6 |
AGEN | Cervical cancer | BLA Filing | 10/22/21 | BLA voluntarily withdrawn October 22, 2021. | 4 |
CLSD | Uveal melanoma including choroidal melanoma | Phase 2 | 2/16/23 | Phase 2 safety and efficacy data presented with an average of nine months of follow-up for patients treated with three cycles of therapy showed response to the therapy with 89-100% tumor control, noted February 16, 2023. | 6 |
IGXT | Acute migraine | Approved | 4/17/23 | Approved April 17, 2023. | 6 |
AQST | Allergic reactions (anaphylaxis) | Phase 2 | 2/24/23 | Phase 2 pharmacokinetic and pharmacodynamic data due presented at AAAAI reported rapid absorption following sublingual administration with the fastest observed median Tmax (12 min forAQST-109, 23 min for EpiPen, and 45 min for IM injection), noted February 24, 2023. | 6 |
AVEO | Hepatocellular carcinoma (HCC) | Phase 1/2 | 1/20/22 | Phase 1b/2 data reported a 27.8% partial response (PR) rate and disease control rate (PR + stable disease) of 67.8%, with a median PFS of 7.3 months and a 1-year OS of 76%, noted January 20, 2022. | 5 |
NKTX | Acute myeloid leukemia / myelodysplastic syndromes | Phase 1 | 6/27/23 | Additional Phase 1 data demonstrated that 4 of 6 patients achieved complete response (67% CR/CRi, 50% CR rate), and 2 CRs with MRD negativity 1 patient deepened response to MRD negative CRi with additional cycles, notedJune 27, 2023. | 6 |
MRK | Ebola | Approved | 8/3/23 | Approval in children aged 12 months and older on August 3, 2023. | 6 |
JAGX | Cancer related diarrhea (CRD) | Phase 2 | 12/10/21 | Phase 2 results reported that CID occurred significantly less (23%) in the crofelemer group during cycle 1 and crofelemer patients were 1.8 times more likely than control patients to have their diarrhea resolved, noted December 10, 2021. | 6 |
ACRS | Rheumatoid arthritis (RA) | Phase 2a | 1/19/21 | Phase 2a 12-week data released January 19, 2021 - generally well tolerated. | 6 |
EOLS | Aesthetics | Phase 2 | 1/28/23 | Phase 2 interim data presented at the 2023 IMCAS World Congress on indicated that the "extra-strength" formulation at 40U (units) achieved a duration profile of 6 months or 26 weeks, noted January 28, 2023. | 6 |
SELB | Tophaceous gout | Phase 2 | 9/30/20 | Phase 2 top-line data released September 30, 2020. Numerically higher response rate on the primary endpoint during months 3 and 6 combined, but did not meet the primary endpoint of statistical superiority. | 4 |
INDV | Bulimia Nervosa | Phase 2 | 2/21/19 | Phase 2 data released February 21, 2019. Endpoints not met. | 4 |
BLRX | Pancreatic ductal adenocarcinoma (PDAC) | Phase 2 | 7/17/23 | Phase 2b trial initiated, noted July 17, 2023. | 5 |
AZN | COVID-19 | Phase 3 | 11/18/21 | Phase 3 separate treatment trial showed an 88% reduced risk of severe COVID-19 or death when treated within three days of symptom onset. | 6 |
ATAI | Generalized Anxiety Disorder (GAD) | Phase 1 | 4/28/23 | Pharmacodynamic data indicated potential for anxiolytic activity without the significant sedative side effects associated with benzodiazepines, noted April 28, 2023. | 5 |
ORIC | Tumors - EGFR/HER2 Exon 20 Inhibitor | Phase 1b | 10/23/23 | Phase 1b initial data presented at ESMO reported responses observed in 2 of 3 EGFR exon 20 patients previously treated with amivantamab (67% ORR), including a confirmed complete response, note October 23, 2023. | 6 |
ANIP | Menopause symptoms | Approved | 9/12/23 | Approved September 12, 2023. | 6 |
LGND | Chronic obstructive pulmonary disease (COPD) | Phase 3 | 12/20/22 | ENHANCE-1 Phase 3 topline data met its primary and key secondary endpoints, noted December 20, 2022. | 5 |
GMAB | Non-Hodgkin Lymphoma (NHL) | Phase 1/2 | 12/14/21 | Phase 1/2 data reported that 25% of patients reported Grade 4 Neutropenia, with a 73% CMR and a 27% PMR, noted December 14, 2021. | 5 |
PFE | HIV for adolescents 12 years and older | Approved | 3/29/22 | Approved March 29, 2022. | 6 |
HRTX | Prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV) | Approved | 8/10/16 | CRL Mar 28 2013. Approved August 10, 2016. | 6 |
VTRS | Multiple sclerosis - Tecfidera generic | Approved | 8/17/20 | FDA approved August 17, 2020. | 6 |
OPK | Obesity and diabetes | Phase 2b | 3/21/19 | Phase 2b top-line data March 21, 2019 met primary endpoint. | 6 |
ONCT | Metastatic castration-resistant prostate cancer (mCRPC) | Phase 1/2 | 8/3/23 | Phase 1/2 study received "Study May Proceed" letter by FDA, noted August 3, 2023. | 5 |
PFE | Pneumococcal Disease | Approved | 4/27/23 | Approved on April 27, 2023. | 6 |
CTMX | Solid tumors | Phase 2 | 3/30/20 | Phase 2 trial has been terminated. | 4 |
CYT | Solid tumors, Ovarian cancer | Phase 1 | 10/12/23 | Additional Phase 1 data reported that two patients had a confirmed partial response, one additional patient achieved an unconfirmed partial response, seven patients had stable disease and one patient had progressive disease, noted October 12, 2023. | 6 |
SNY | Non-small cell lung cancer (NSCLC) | Phase 3 | 9/19/21 | Phase 3 data presented at ESMO September 19, 2021 showed trial met primary and all secondary endpoints, with an objective response rate of 43%. | 6 |
AGEN | Solid tumors, melanoma | Phase 1 | 6/3/23 | Phase 1 data at ASCO reported an overall response rate (ORR) was 11% (n=2); 37% had SD (n=7) resulting in a disease control rate (DCR) (CR, PR or SD) of 47%, noted June 3, 2023. | 5 |
ANAB | Generalized pustular psoriasis | Phase 3 | 10/9/23 | Phase 3 top-line data met its primary endpoint in the study population achieving rapid clearance of pustulation, erythema and scaling through Week 4 after a single dose of 750mg IV imsidolimab. Top-line data also demonstrate a favorable safety and tolerability profile, noted October 9, 2023. | 6 |
ANAB | Acne | Phase 2 | 3/14/22 | Phase 2 data reported that the trial did not meet the primary or secondary endpoints, noted March 14, 2022. | 6 |
BPMC | RET-fusion non-small cell lung cancer (NSCLC) | Approved | 9/4/20 | FDA Approval announced September 4, 2020. | 6 |
AZN | Second-line ovarian cancer | Approved | 8/17/17 | Approval announced August 17, 2017. | 6 |
PULM | Allergic bronchopulmonary aspergillosis in patients with asthma. | Phase 1 | 7/17/18 | Phase 1 Part 3 data released July 17, 2018 - safe and well tolerated | 6 |
CPIX | Pain and fever in patients three months to six months of age | Approved | 5/15/23 | Expanded label approval by FDA on May 15, 2023. | 6 |
MRK | Neurofibromatosis type 1 plexiform neurofibromas | Approved | 4/13/20 | FDA Approval announced April 13, 2020. | 6 |
NBIX | Endometriosis | Approved | 7/24/18 | FDA approval announced July 24, 2018. | 6 |
SNGX | Cutaneous T-Cell Lymphoma (CTCL) cancer | Phase 3 | 5/4/23 | Phase 3 data results confirm and extend response results, noted May 4, 2023. | 5 |
BMY | Non-small cell lung cancer (NSCLC) | Phase 3 | 10/23/23 | Phase 3 data presented at ESMO reported that 3-y EFS and OS rates were 72% vs 47% and 85% vs 66%, respectively, noted October 23, 2023. | 6 |
BHVN | Spinocerebellar Ataxia (SCA) | Phase 3 | 7/27/23 | The FDA informed Biohaven that it would not review the recently submitted NDA application for troriluzole given that the study's primary endpoint was not met and thus, would not permit a substantive review. The communication from the FDA indicated that the Company may request a Type A meeting within 30 days, noted July 27, 2023. | 6 |
TCDA | Chronic kidney disease | CRL | 8/24/20 | CRL announced August 24, 2020. | 5 |
MNPR | Oral mucositis | Phase 2/3 | 3/27/23 | Phase 2b/3 interim analysis conducted by an independent Data Safety Monitoring Board (DSMB), which informed the Company that the trial did not meet the pre-defined threshold for efficacy of a 15% absolute difference in SOM prevention between Validive and placebo. Based on not meeting the pre-specified efficacy threshold, the company will be discontinuing the study, noted March 27, 2023. | 6 |
TGTX | Chronic Lymphocytic Leukemia | Phase 1/2 | 9/20/21 | Phase 1/2 data demonstrated that 47 patients have now been treated as of the data cutoff with 57% of patients previously exposed to a BTK inhibitor, best Overall Response Rate (ORR) was 100% amongst evaluable patients (n=46), including 37% complete response (CR) rate presented at iwCLL September 20, 2021. | 6 |
ARDS | Cystic Fibrosis | Phase 2a | 3/13/23 | Phase 2a trial met primary and secondary endpoints, noted March 13, 2023. | 5 |
NVO | Obesity | Phase 2 | 6/18/20 | Phase 2 primary endpoint met - June 18, 2020. | 6 |
LGND | Chronic obstructive pulmonary disease (COPD) | Phase 2 | 10/13/21 | Phase 2 part B data noted when administered by hand-held pMDI over one week treatment provided clinically meaningful, statistically significant and dose-dependent bronchodilation, noted October 13, 2021. | 6 |
IONS | Amyotrophic lateral sclerosis (SOD1-ALS) | Approved | 4/25/23 | FDA granted accelerated approval on April 25, 2023. | 6 |
EIGR | COVID-19 | Phase 3 | 3/17/22 | Phase 3 top-line data reported a probability of superiority of 99.91%, with a 60% reduced risk of COVID-19-related death, noted March 17, 2022. | 6 |
TPST | Hepatocellular Carcinoma (HCC), Solid tumors | Phase 1/2 | 4/17/23 | Additional biomarker data presented at AACR reported on-target changes in gene signatures in the peripheral blood that were dependent upon drug exposure levels, noted April 17, 2023. | 6 |
REGN | Eosinophilic esophagitis (EoE) in 1-11 year olds | Phase 3 | 7/14/22 | Phase 3 data reported that trial met its primary endpoint, noted July 14, 2022. | 5 |
MRK | Pancreatic cancer | Approved | 12/30/19 | FDA Approval announced December 30, 2019. | 6 |
XFOR | Waldenström macroglobulinemia | Phase 1b | 12/13/21 | Phase 1b data of 16 patients enrolled demonstrated that 14 were evaluable as of the data cut, all at low- (200 mg) and mid-level (400 mg) dosing; median duration of treatment was 272.5 days (range 33-435 days); 12 patients remain on study. CXCR4 antagonism proof of concept established, with 100% overall response rate. | 6 |
LLY | Crohn's disease | Phase 3 | 10/12/23 | Phase 3 trial met the co-primary and all major secondary endpoints, noted October 12, 2023. | 5 |
FATE | B-cell Leukemias and Lymphomas | Phase 1 | 12/10/22 | Phase 1 interim data reported that 1 of 2 patients naïve to CAR T-cell therapy achieved an objective response (1 CR) at Day 30, and 2 of 6 patients previously treated with CAR T-cell therapy achieved an objective response (1 CR, 1 PR) at Day 30, noted December 12, 2022. | 6 |
AMGN | Immune Thrombocytopenia (Pediatric) | Approved | 12/14/18 | FDA approval announced December 14, 2018. | 6 |
ERAS | Glioblastoma Multiforme | Phase 1 | 6/22/23 | DA granted orphan drug designation (ODD), noted June 22, 2023. | 5 |
LUMO | Pediatric Growth Hormone Deficiency (PGHD) | Phase 2 | 6/21/23 | Phase 2 interim data shared at KOL demonstrate a durable response to LUM-201 from 6 to 12 months, noted June 21, 2023. | 6 |
LPTX | Gastric / Gastroesophageal Junction Cancer | Phase 2 | 6/5/23 | Phase 2 data shared at ASCO reported that the median overall survival (OS) was 19.5 months and median progression-free survival (PFS) was 11.3 months, noted June 5, 2023. | 5 |
INVA | Beta thalassemia patients suffering from iron overload | Phase 3 | 11/25/19 | Development to be discontinued due to lack of efficacy - November 25, 2019. | 4 |
MNKKQ | Hepatorenal syndrome (HRS) Type 1 | CRL | 2/22/22 | CRL reissued February 22, 2022. | 5 |
HRMY | Adult Epilepsy Patients with Refractory Focal Seizures | Phase 2 | 8/7/17 | Phase 2 data released August 7, 2017 - endpoints not met. | 4 |
MYOV | Endometriosis-associated pain | Approved | 8/5/22 | Approved August 5, 2022. | 6 |
VTGN | Major depressive disorder (MDD) | Phase 1 | 6/21/23 | Phase 1 study results showed that dosing was well-tolerated and demonstrated a favorable safety and tolerability profile across single and multiple dose intranasal administrations, noted June 21, 2023. | 6 |
DTIL | Relapsed or refractory B-cell precursor acute lymphoblastic leukemia and R/R non-hodgkin lymphoma | Phase 1/2 | 6/8/22 | Phase 1/2 clinical update reported an 100% ORR, 73% CR rate and 50% durable response rate greater than six months, noted June 8, 2022. | 5 |
BMY | Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM) | Approved | 6/16/23 | FDA Approval on June 16, 2023 | 6 |
PFE | Amyotrophic lateral sclerosis (ALS) | Phase 3 | 9/29/22 | Phase 3 trial did not meet its primary endpoint, noted September 29, 2022. | 6 |
BNOX | Post-Traumatic Stress Disorder (PTSD) | Phase 2b | 9/28/23 | Phase 2b topline data met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks. Statistically significant secondary endpoints showed improvements in depressive symptoms and sleep, noted September 28, 2023. | 6 |
TAK | Eosinophilic esophagitis | CRL | 12/21/21 | CRL December 21, 2021. | 5 |
ARGX | Pemphigus foliaceous and vulgaris (PV) | Phase 2 | 6/20/18 | Phase 2 interim data released June 20, 2018, disease control observed in 4/6 patients. | 6 |
GILD | Hepatitis B virus (HBV) infection in pediatric patients 12 years of age and older | Approved | 11/2/22 | Approved November 2, 2022. | 6 |
JNJ | Waldenström’s Macroglobulinemia | Approved | 8/27/18 | FDA approval announced August 27, 2018. | 6 |
HALO | Multiple Myeloma | Approved | 12/1/21 | Approved December 1, 2021. | 6 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.